New dog therapies help boost Pfizer's top line

Drug researchers at Pfizer have come up with a series of new therapies for dogs. The drug Cerenia, which helps prevent motion sickness in dogs, has now been approved. And researchers recently cheered the development of Slentrol for weight control. Therapies for non-humans now accounts for $632 million in revenue at Pfizer. That's less than six percent of its income, but a sign that as people spend growing sums on their pets, drug development in the animal world is likely to become increasingly lucrative.

- read the report from the Wall Street Journal's health blog (sub. req.)

Related Article:
Veterinary drugs draw scrutiny. Report

Suggested Articles

Treating mice with niacin increased the number of immune cells in glioblastomas, reducing tumor size and extending survival.

Efforts to pivot existing discoveries into COVID-19 cures may not bear fruit until the pandemic has ended but could help fend off future outbreaks.

GigaGen joined a group of companies making plasma-based, polyclonal antibody treatments for COVID-19.